Ulu A - Search Results

1

The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism.

Oguzulgen IK, Yilmaz E, Demirtas S, Erkekol FO, Ekim N, Demir N, Numanoglu N, Ozel D, Ulu A, Akar N. Oguzulgen IK, et al. Among authors: ulu a. Clin Appl Thromb Hemost. 2009 Feb;15(1):73-7. doi: 10.1177/1076029607305110. Epub 2007 Dec 26. Clin Appl Thromb Hemost. 2009. PMID: 18160588 Free article.

2

High plasma levels of factor VIII: an important risk factor for isolated pulmonary embolism.

Erkekol FO, Ulu A, Numanoglu N, Akar N. Erkekol FO, et al. Among authors: ulu a. Respirology. 2006 Jan;11(1):70-4. doi: 10.1111/j.1440-1843.2006.00786.x. Respirology. 2006. PMID: 16423204

3

The importance of thrombotic risk factors in the development of idiopathic sudden hearing loss.

Yildiz Z, Ulu A, Incesulu A, Ozkaptan Y, Akar N. Yildiz Z, et al. Among authors: ulu a. Clin Appl Thromb Hemost. 2008 Jul;14(3):356-9. doi: 10.1177/1076029607306399. Epub 2007 Dec 26. Clin Appl Thromb Hemost. 2008. PMID: 18160602 Free article.

4

Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.

Eroglu A, Ulu A, Cam R, Akar N. Eroglu A, et al. Among authors: ulu a. J BUON. 2006 Oct-Dec;11(4):481-4. J BUON. 2006. PMID: 17309181

5

Factor V gene (1691A and 4070G) and prothrombin gene 20210A mutations in patients with Behçet's disease.

Ateş A, Düzgün N, Ulu A, Tiryaki AO, Akar N. Ateş A, et al. Among authors: ulu a. Pathophysiol Haemost Thromb. 2003 May-Jun;33(3):157-63. doi: 10.1159/000077824. Pathophysiol Haemost Thromb. 2003. PMID: 15170396

6

Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients with and without thrombosis.

Eroglu A, Ulu A, Akar N. Eroglu A, et al. Among authors: ulu a. J Thromb Thrombolysis. 2006 Oct;22(2):111-2. doi: 10.1007/s11239-006-9054-z. J Thromb Thrombolysis. 2006. PMID: 17008976 No abstract available.

7

Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.

Eroglu A, Ulu A, Cam R, Kurtman C, Akar N. Eroglu A, et al. Among authors: ulu a. J Thromb Thrombolysis. 2007 Feb;23(1):31-4. doi: 10.1007/s11239-006-9001-z. J Thromb Thrombolysis. 2007. PMID: 17106650

8

EPCR gene A3 haplotype and elevated soluble endothelial protein C receptor (sEPCR) levels in Turkish pediatric stroke patients.

Ulu A, Gunal D, Tiras S, Egin Y, Deda G, Akar N. Ulu A, et al. Thromb Res. 2007;120(1):47-52. doi: 10.1016/j.thromres.2006.08.004. Epub 2006 Oct 5. Thromb Res. 2007. PMID: 17027065 Clinical Trial.

9

Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients.

Eroglu A, Ulu A, Cam R, Akar N. Eroglu A, et al. Among authors: ulu a. J BUON. 2007 Jan-Mar;12(1):135-6. J BUON. 2007. PMID: 17436417 No abstract available.

10

The correlation between soluble endothelial protein c receptor (sEPCR) and tumor necrosis factor-alpha (TNF-α) levels in vivo.

Ulu A, Egin Y, Akar N. Ulu A, et al. Turk J Haematol. 2008 Jun 5;25(2):108-9. Turk J Haematol. 2008. PMID: 27264452 English. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters